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Introduction {#ehf212354-sec-0004}
============

Chronic heart failure accounts for a substantial amount of morbidity and mortality worldwide.[1](#ehf212354-bib-0001){ref-type="ref"} Although not yet an established therapy, structural myocardial regeneration may benefit an enormous population.[2](#ehf212354-bib-0002){ref-type="ref"} Pressure‐controlled intermittent coronary sinus occlusion (PICSO), a trans‐coronary sinus catheter intervention, was primarily developed to salvage jeopardized myocardium during acute ischemic syndromes. It has been shown that PICSO intervention leads to the activation of important growth factors such as vascular endothelial growth factor and interleukin 6, which in turn may stimulate cardiac regeneration via cardiomyocyte proliferation.[3](#ehf212354-bib-0003){ref-type="ref"} Recently, a report on PICSO in acute heart failure patients suggests recovery beyond myocardial salvage.[4](#ehf212354-bib-0004){ref-type="ref"} We hypothesized that PICSO with its periodic ventricularization of the coronary venous compartment may modify the concentration of molecules relevant to commence developmental pathways.

Aims {#ehf212354-sec-0005}
====

We aimed to investigate the effects of PICSO on the release of soluble molecules linked to myocardial development through direct comparisons among pre‐intervention and post‐intervention sera and equivalent control sera. Furthermore, we aimed to investigate the effects of released molecules on cellular events.

Methods {#ehf212354-sec-0006}
=======

Study population {#ehf212354-sec-0007}
----------------

Patients with advanced heart failure undergoing cardiac resynchronization therapy (CRT) implantation and older than 18 years of age were eligible for this study. Exclusion criteria included the presence of [prosthetic](http://www.dict.cc/englisch-deutsch/prosthetic.html) [heart](http://www.dict.cc/englisch-deutsch/cardiac.html) [valve](http://www.dict.cc/englisch-deutsch/valve.html)s or indication for [valve](http://www.dict.cc/englisch-deutsch/valve.html) [replacement](http://www.dict.cc/englisch-deutsch/replacement.html), unstable angina pectoris, known bleeding disorder, chronic steroid therapy, cancer, infectious diseases of any cause, pregnancy, and haemodynamic or electrical instability. All subjects provided written informed consent. The study protocol and all procedures involved complied with the Declaration of Helsinki and were approved by the Ethics Committee of the Medical University of Vienna.

Study protocol {#ehf212354-sec-0008}
--------------

The study took place in the electrophysiology operating suite during CRT device implantation. After left ventricular electrode placement within the coronary veins and electrical threshold testing, a specially designed coronary sinus catheter with a curved tip and a helium inflatable balloon was used for the application of PICSO (Contract Medical International, Dresden, Germany). Periodic coronary sinus pressure (CSP) elevation was achieved using an automated PICSO controller (ARC Seibersdorf Research GmbH, Seibersdorf, Austria).

Analysis of the collected sera {#ehf212354-sec-0009}
------------------------------

To investigate the effects of PICSO on the release of soluble factors, coronary sinus blood samples before and after 20 min of treatment or the respective time in control patients were taken. Samples were then centrifuged and shock frozen for storage at −80°C. MicroRNA and proteomics analyses were performed subsequently. As shown in *Figure* [*1*](#ehf212354-fig-0001){ref-type="fig"}, sera from coronary sinus blood were co‐cultured with a mixture of human fibroblasts and adult cardiomyocytes stemming from the septum of a failing heart from a patient undergoing heart transplantation and commercially available human fibroblasts.

![Study protocol and serum collection. (A) After advancement of a coronary sinus catheter and temporary pressure‐controlled occlusion (PICSO) of a major portion of outflow from coronary veins, pressures are increased as seen in (B); systolic pressures peaks are thought to be the driving force to activate venous endothelium. (C) Immediately frozen to −80°, (D) human fibroblasts and cardiomyocytes are co‐cultured with patient sera to estimate the proliferative power of each serum. After primary culture, cells underwent a starving period before co‐cultured with patient serum.](EHF2-5-1176-g001){#ehf212354-fig-0001}

Statistical analysis {#ehf212354-sec-0010}
--------------------

Statistical analyses were performed using SPSS for Windows V20 (SPSS Inc., Chicago, IL, USA). The measurements are expressed as mean ± standard deviation. Preoperative patients\' characteristics were compared using χ^2^ tests; in terms of *n* \< 5 in one group, the Fisher\'s exact test was performed. An alpha error below *P* = 0.05 was considered indicative of a statistically significant difference.

Results {#ehf212354-sec-0011}
=======

Study population {#ehf212354-sec-0012}
----------------

Thirty‐two patients after successful CRT implantation were included in the study. Eight patients were investigated with PICSO for 20 min, and 24 patients constituted the control group. Between the two groups, no significant differences were noted at baseline.

Demographics and clinical data {#ehf212354-sec-0013}
==============================

*Table* [1](#ehf212354-tbl-0001){ref-type="table"} depicts demographics and clinical data, showing comparable parameter in both groups.

###### 

summary of demographics and clinical data

                                             PICSO (*n* = 8)   Control (*n* = 24)  *P*‐value (χ^2^ and Fisher\'s exact test[b](#ehf212354-note-0005){ref-type="fn"})
  ----------------------------------------- ----------------- -------------------- -----------------------------------------------------------------------------------
  Demographics                                                                     
  Age (years) ± SD (*n*)                      73.25 ± 10.78       64.75 ± 11.0     0.076[a](#ehf212354-note-0004){ref-type="fn"}
  Gender (*N* and % male)                           7                  17          0.346
                                                  87.5%              70.83%        
  Ejection fraction (%)                       23.13 ± 6.94        25.70 ± 8.20     0.433[a](#ehf212354-note-0004){ref-type="fn"}
  Clinical history                                                                 
  Diabetes                                          2                  6           1
                                                   25%                25%          
  COPD                                              1                  7           0.642
                                                  12.5%              29.17%        
  Hyperlipidaemia                                   6                  17          1
                                                   75%               70.83%        
  Hypertension                                      8                  20          0.217
                                                  100%               83.33%        
  Smoking                                           3                  6           0.654
                                                  37.5%               25%          
  Previous stroke                                   1                  1           0.444
                                                  12.5%              4.17%         
  Previous myocardial infarction                    3                  12          0.691
                                                  37.5%               50%          
  Valvular disease                                  3                  10          1
                                                  37.5%              41.67%        
  Chronic atrial fibrillation (anamnesis)           1                  10          0.209
                                                  12.5%              41.67%        
  Atrial fibrillation at admission                  0                  4           0.550
                                                   0%                16.67%        
  Dilated CMP                                       5                  9           0.217
                                                  62.5%              37.5%         
  Ischaemic CMP                                     3                  14          0.423
                                                  37.5%              58.33%        
  Valvular CMP                                      0                  1           1
                                                   0%                4.17%         
  Conduction abnormalities                                                         
  Left bundle branch block                          5                  17          0.66
                                                  62.5%              70.83%        
  Right bundle branch block                         0                  3           0.555
                                                   0%                12.5%         
  AV block                                          0                  4           0.550
                                                   0%                16.67%        
  Medications                                                                      
  Beta‐blocker                                      8                  20          0.217
                                                  100%               83.33%        
  ARB or ACE inhibitor                              8                  21          0.294
                                                  100%               87.5%         
  Diuretic                                          8                  20          0.217
                                                  100%               83.33%        
  Lipid‐lowering agent                              5                  12          0.539
                                                  62.5%               50%          
  Device                                                                           
  CRT‐D                                             4                  18          0.218
  CRT‐P                                             4                  6           

ARB, angiotensin receptor blocker; ACE, angiotensin‐converting enzyme; AV, atrioventricular; CMP, cardiomyopathy; COPD, chronic obstructive pulmonary disease; CRT‐D, cardiac resynchronization therapy defibrillator; CRT‐P, cardiac resynchronization therapy pacemaker; PISCO, pressure‐controlled intermittent coronary sinus occlusion; SD, standard deviation.

Evaluated using the unpaired Student\'s *t*‐test.

Fisher analysis was used if *n* \< 5.

Parameters during the intervention {#ehf212354-sec-0014}
----------------------------------

In PICSO patients, the mean CSP before the intervention was 11.7 and 12.1 mmHg after the intervention. During the intervention, CSP systolic pressures rose 107% to mean 24.2 mmHg CSP with systolic peaks of 52 mmHg.

Effects of pressure‐controlled intermittent coronary sinus occlusion on soluble factors secreted into cardiac veins {#ehf212354-sec-0015}
-------------------------------------------------------------------------------------------------------------------

### MicroRNA {#ehf212354-sec-0016}

The time courses of microRNA in both groups were monitored revealing distinguished trends. This difference (as reported by the comparison of the difference normalized Ct post‐value minus normalized Ct baseline) was statistically significant for 16 of the tested microRNAs (*Figure* [*2*](#ehf212354-fig-0002){ref-type="fig"}). In the PICSO group, we observed a relative increase of miR‐19b, miR‐101, miR‐143, miR‐144, and miR‐145. A gene enrichment analysis of the data emphasized possible candidate pathways to belong to the Wnt pathway (miR‐101 and miR‐144), muscle organ development (miR‐101 and miR‐144) or muscle (miR‐143), aortic and coronary endothelial function (miR‐144), and muscle contraction (miR‐19b). In parallel, the concentrations of let‐7b, miR‐25, miR‐191, miR‐320b, miR‐421, and miR‐486‐5p were relatively reduced.

![Differentially expressed microRNA (miRNA). Here, we show differentially expressed miRNA for both groups. Delta differences between first and second serum collection are shown as mean ddCP for both groups. After normalization of data to global mean, a delta Cq value is obtained (dCq). Differences in expression levels are calculated as dCq (1) − dCq (2) = ddCq. Only statistically significant patterns of miRNA expression are shown. miRNA 145 is involved in a double negative feedback loop with Krüppel‐like factor 4 inducing lineage restricted differentiation. PICSO, pressure‐controlled intermittent coronary sinus occlusion.](EHF2-5-1176-g002){#ehf212354-fig-0002}

In the control group with resynchronization only, miR‐421, let‐7b, miR‐485‐5p, miR‐25, miR‐191, miR‐30d, miR‐584, and miR‐320b were increased, and miR‐19b, miR‐144, miR‐143, miR‐101, miR‐145, miR‐107, and miR‐363 were decreased.

Thus, these data suggest that PICSO treatment had several significant effects on the circulating plasma microRNA in comparison with the control group.

Clinical observation and the mechanotransduction effect induced by PICSO intervention indicate a domain change between epigenetic forces and genome, a transition of hemodynamic impulses into a pleiotropic molecular signalling pulse as suggested by significant changes in coronary sinus plasma levels of several microRNAs. Regulation of cardiogenic gene expression by microRNA has been shown to play a prominent role in heart development. Recent data have identified various microRNAs as critical regulators of the proper differentiation, proliferation, and survival of cardiomyocytes, endocardial cells, epicardial cells, and neural crest cells. The potential of influencing microRNA expression may therefore be utilized in management and prevention of cardiovascular diseases.[5](#ehf212354-bib-0005){ref-type="ref"}

A number of studies demonstrated that elevated levels of miR‐143 and miR‐145 play an important role in regulating several transcription factors like octamer‐binding transcription factor 4, sex*‐*determining region Y*‐*box 2, and Krüppel‐like factor 4 (KLF‐4) as well as promoting differentiation and simultaneously repressing proliferation of vascular smooth muscle cells. The significant increase in plasma levels of miR‐143 and miR‐145 in PICSO‐treated patients together with the significant up‐regulation of KLF‐4 is suggestive of activation of such pathways. There are also a series of other differentially up‐regulated microRNA influencing microRNA.

Whereas let‐7b, let‐7g, and miR‐30d have been found in some studies to be involved in epithelial mesenchymal transformation and angiogenesis as well as improvement of contractility and are therefore considered positive in regenerative molecular pathways; in our patient series, the levels are lower in PICSO than in controls, requiring careful interpretation in the context of multiple intertwined processes and ambivalent responses of individual evoked signals in context especially when induced in failing myocardium.

### Transcription factors {#ehf212354-sec-0017}

Several transcription factors sampled from coronary venous blood reacted to the PICSO intervention and to lead testing (*Table* [2](#ehf212354-tbl-0002){ref-type="table"}), suggesting group difference especially in 49 kDa MEF2C, a morphogen involved in cardiac morphogenesis, the development of myogenesis and vasculature, and increase in PICSO patients, whereas it remained unchanged in controls. As seen in spite of the small number, pre‐values and post‐values react in both groups to surgery and the intervention, showing a complex matrix, which deserves larger patient cohorts for meaningful interpretation. As reaction to soluble factors released, KLF‐4 was up‐regulated in explanted human myocardium from transplant recipients co‐cultured with post‐PICSO sera based on protein levels (*Figure* [*3*](#ehf212354-fig-0003){ref-type="fig"}).

###### 

Transcription factors in cardiac venous blood

                           Pre‐values   Post‐values                                  
  -------------- --------- ------------ ------------- ----------- --------- -------- ----------------------
  39 kDa FGF5    PICSO     1590.06      767.70        1720.25     1195.02   0.3461   108.19
  39 kDa FGF5    Control   5355.90      3002.89       5141.62     2637.02   0.2887   96.00
  36 kDa FGF5    PICSO     2280.27      2214.61       2943.83     3000.44   0.2191   129.10
  36 kDa FGF5    Control   3521.64      2600.49       2765.38     2449.93   0.1312   78.53
  35 kDa FGF5    PICSO     4939.24      2099.17       5428.65     1682.89   0.1843   109.91
  35 kDa FGF5    Control   4395.15      972.55        4987.40     1195.45   0.0858   113.48
  33 kDa FGF5    PICSO     420.00       387.83        408.00      377.30    0.4518   97.14
  33 kDa FGF5    Control   760.04       316.19        724.87      293.82    0.3898   95.37
  60 kDa TBX5    PICSO     1765.94      863.50        1312.97     1055.07   0.0199   74.35 (*P* \< 0.05)
  60 kDa TBX5    Control   3923.35      2434.77       3420.49     2564.07   0.0392   87.18 (*P* \< 0.05)
  51 kDa TBX5    PICSO     15 583.03    9002.37       13 358.04   6304.52   0.1031   85.72
  51 kDa TBX5    Control   18 691.01    3699.77       16 532.11   3648.23   0.0008   88.45 (*P* \< 0.05)
  41 kDa TBX5    PICSO     9052.13      7431.67       4229.24     4571.33   0.0343   46.72 (*P* \< 0.05)
  41 kDa TBX5    Control   8670.12      9768.61       4512.81     4529.47   0.0409   52.05 (*P* \< 0.05)
  48 kDa GATA4   PICSO     11 881.95    1853.15       9155.60     4549.00   0.2165   77.05
  48 kDa GATA4   Control   20 211.56    8359.36       11 642.15   6247.43   0.0010   57.60 (*P* \< 0.05)
  52 kDa MEF2C   PICSO     2022.00      783.74        2424.36     1290.11   0.1877   119.90
  52 kDa MEF2C   Control   2445.52      1038.12       2940.57     1197.48   0.0441   120.24 (*P* \< 0.05)
  49 kDa MEF2C   PICSO     8211.22      1830.25       10 197.42   1832.86   0.0232   124.19 (*P* \< 0.05)
  49 kDa MEF2C   Control   11 319.58    2698.46       11 750.39   3171.96   0.1896   103.81
  39 kDa HAND2   PICSO     364.73       480.48        1041.79     555.15    0.1341   285.64
  39 kDa HAND2   Control   936.69       664.02        1641.70     627.79    0.0336   175.27 (*P* \< 0.05)
  36 kDa HAND2   PICSO     1645.37      659.21        905.55      690.90    0.1317   55.04
  36 kDa HAND2   Control   1285.81      800.58        796.52      442.24    0.0584   61.95
  35 kDa HAND2   PICSO     2853.06      1721.25       2057.02     945.99    0.1313   72.10
  35 kDa HAND2   Control   4247.16      864.58        3927.03     1265.71   0.1962   92.46
  31 kDa HAND2   PICSO     11 503.93    3422.18       14 250.30   3086.66   0.1367   123.87
  31 kDa HAND2   Control   9523.03      4450.82       13 858.94   4506.63   0.0032   145.53 (*P* \< 0.05)

SD, standard diviation; PISCO, pressure‐controlled intermittent coronary sinus occlusion.

Transcription factors sampled from coronary venous blood in relation to pre‐interventional and post‐interventional values in both groups show a complex pattern of reactions in both groups. A potential interventional effect of PICSO can only be suspected in 49 kDa MEF2C. To allow sophisticated interpretation, a larger cohort of patients is needed.

![Krüppel‐like factor 4 (KLF‐4) in cardiomyocytes after serum exposure. Cardiomyocytes supravitally sampled from transplant recipient hearts were exposed to serum collected in three control and three pressure‐controlled intermittent coronary sinus occlusion (PICSO) patients according to protocol. Pre‐control and post‐control were set as baseline fluorescence intensity to compare signal differences in PICSO patients. Blue bar, 30 min; red bar, 60 min; orange, 120 min after treatment start. Groups are indicated on the bottom. Bars indicate fold change to control group as defined as 1. Mean fold change is given above error bars of standard deviation. Signalling of sera co‐cultured seem to peak at 60 min and decline thereafter.](EHF2-5-1176-g003){#ehf212354-fig-0003}

Proliferation results {#ehf212354-sec-0018}
---------------------

There was a significant difference in the proliferation of human fibroblasts in the PICSO group compared with the control group. The growth curve generated via real‐time cell analysis RTCA software revealed that fibroblast growth before and after PICSO‐treated serum had distinctive trend for cell proliferation profile. Serum sample from after PICSO treatment showed significant increase in cell index immediately after sample addition. Results are depicted in (*Figure* [*4*](#ehf212354-fig-0004){ref-type="fig"}).

![Real‐time cell index for (A) human primary cardiomyocytes sampled from an explanted heart from a patient with heart failure during transplantation and (B) commercially available fibroblasts cultured in the presence of PICSO (*n* = 5 patients) or non‐PICSO (*n* = 6 patients) sera from pre‐procedure and post‐procedure. Cells index was measured up to 250 and 144 h for fibroblast and primary cardiomyocytes, respectively. Student\'s *t*‐test significance is given in the graphs on the right for comparisons among groups at the end of the measurement periods. Note that post‐PICSO sera induced additional proliferation, whereas in post‐control sera, no change was evident.](EHF2-5-1176-g004){#ehf212354-fig-0004}

Conclusions {#ehf212354-sec-0019}
===========

The key element of our exploratory study is the association of a temporary pressure increase in coronary veins leading to molecular changes known to be involved in cardiac development. There appears to be a causative sequence between the haemodynamic, 'epigenetic' impulse of temporarily elevated coronary venous pressure via mechanotransduction and the activation of coronary venous vascular cells.[6](#ehf212354-bib-0006){ref-type="ref"} As proposed in the 'embryonic recall hypothesis,' this activation and subsequent mechanotransduction via primary cilia and cytoskeleton of venous endothelium induce a burst of a differential pattern of microRNA in PICSO‐treated patients together with the induction of several transcription factors, as secreted morphogens may be the key phenomenon that connects the adult failing heart to innate but dormant cardiac developmental pathways.[7](#ehf212354-bib-0007){ref-type="ref"} The up‐regulation of miR‐143 in PICSO‐treated patients, as well as the findings by Miyasaka *et al*. in the developing heart during the first heartbeat, supports our hypothesis in this context.[8](#ehf212354-bib-0008){ref-type="ref"} In agreement to Marfella *et al*., investigating soluble factors as prognostic biomarkers in CRT patients, flow‐sensitive miRNA 145‐5p increased compared with controls in our verum group.[9](#ehf212354-bib-0009){ref-type="ref"} Importantly, the effects reported relate to secretion of molecules, rather than *de novo* synthesis of morphogens, as the post‐procedure timing for assessment was limited to 20 min. However, long‐lasting signalling and the induction of a molecular cascade might lead via a domino effect to structural regeneration.[10](#ehf212354-bib-0010){ref-type="ref"}

In summary, PICSO modulated the expression of several relevant microRNA, which were detectable in blood of the coronary sinus. The resulting microRNA pattern indicates a situation favouring cardiac regeneration by action on cardiomyocytes and cardiac fibroblasts as well as by prevention of stress‐related antiangiogenetic effects.

Our observations also suggest that reconnecting adult failing hearts with cardiac development and therefore innate dormant process can be revived and eventually may be used to reverse the vicious cycle of severe symptoms in patients with otherwise untreatable heart failure.

We postulate that application of PICSO in a controlled trial in patients with severe chronic heart failure will substantiate the clinical significance of these molecular findings.
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